Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 5.64B P/E 32.22 EPS this Y 43.70% Ern Qtrly Grth 24.70%
Income 337.29M Forward P/E 11.74 EPS next Y 19.30% 50D Avg Chg 16.00%
Sales 873.3M PEG 0.51 EPS past 5Y 71.85% 200D Avg Chg -2.00%
Dividend N/A Price/Book 85.70 EPS next 5Y 28.00% 52W High Chg -28.00%
Recommedations 2.40 Quick Ratio 5.58 Shares Outstanding 126.68M 52W Low Chg 44.00%
Insider Own 1.08% ROA 13.38% Shares Float 125.34M Beta 1.28
Inst Own 98.32% ROE 153.16% Shares Shorted/Prior 9.64M/9.67M Price 42.85
Gross Margin 70.93% Profit Margin 38.62% Avg. Volume 1,156,193 Target Price 61.56
Oper. Margin 50.67% Earnings Date Nov 4 Volume 979,812 Change 1.35%
About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Halozyme Therapeutics, Inc. News
09:40 AM Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
11/19/24 3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
11/19/24 HALO vs. FOLD: Which Stock Should Value Investors Buy Now?
11/19/24 Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now?
11/19/24 Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?
11/18/24 Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
11/17/24 Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says
11/15/24 Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
11/15/24 Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
11/15/24 Halozyme Submits $2.11 Billion Acquisition Offer For Evotec
11/15/24 Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid
11/15/24 Halozyme bids for Evotec; BeiGene gets a new name
11/15/24 Germany’s Evotec Gets Takeover Interest From Halozyme
11/14/24 Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
11/08/24 Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today
11/05/24 Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
11/03/24 Results: Halozyme Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
11/01/24 Top High Growth Tech Stocks To Watch In November 2024
11/01/24 Halozyme Announces Record Earnings, Guidance
11/01/24 HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up
HALO Chatroom

User Image NobVega Posted - 26 minutes from now

$HALO Should have gone with intuition and sold all stock here at a loss and easily made it back with Intuitive Machines $LUNR. Expect once I do, Helen will call the unwinding offer back and it goes back to $60 where this shit started.

User Image MAXGMAN Posted - 5 minutes from now

$HALO https://www.nasdaq.com/articles/breaking-down-halozyme-therapeutics-10-analysts-share-their-views

User Image NobVega Posted - 49 minutes ago

$HALO Evotec has already said no thanks. Wall Street said no thanks. When Halo management says ok forget about it, we go up $10. We're waiting Ms Helen.

User Image Sean29md Posted - 18 hours ago

$HALO Brand new Bristol study with Halozyme/Enhanze: https://clinicaltrials.gov/study/NCT06697197?intr=rHuPH20&sort=StudyFirstPostDate&rank=1

User Image NobVega Posted - 1 day ago

$HALO $68 target maintained by HC Wainwright. Well alright then, deal must be called off or outright rejected. Soon as Helen confirms, I'll add. She should look to sell the company. That's what Wall Street is about. Make money for shareholders Helen. Young uns need to be Fed. Still down $18 from announcement. Is that going to be your legacy? Be Jake Paul, not Mike Tyson. Thanks.

User Image Thestocktraderhubzee Posted - 1 day ago

$HALO HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $68 Price Target

User Image Sean29md Posted - 1 day ago

$HALO ARGX Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies https://ih.advfn.com/stock-market/NASDAQ/argenx-ARGX/stock-news/94954309/form-6-k-report-of-foreign-issuer-rules-13a-16

User Image Stocksrunner Posted - 1 day ago

stocks bouncing back! $BGS is climbing from its $6.21 support, now at $6.36 with rsi rising to 30.28. $CLVT surges 5.41% to $4.87, edging closer to $4.57 support. $DEO, steady at $119.20, shows an oversold rsi of 30.40, hinting at potential. $EWCZ rockets 7.27% to $5.90 with $5.50 as key support, while $HALO jumps 5.26%, now at $44.81. timing’s key—watch for stronger breakouts past resistance for those golden entries!

User Image OptionRunners Posted - 1 day ago

$HALO Buyer of the March 21st $50/$60 call spreads 1,000 times for $2.20

User Image Sean29md Posted - 1 day ago

$HALO This whole episode with Evotec has been helpful for the investors and the BOD in testing Helen one more time. If she shows discipline and walks away from this acquisition after hearing a resounding "NO" from halo investors and market participants, she will regain respect and trust. We also learned which posters here are objective longs vs. Helen's cheerleaders. Some of see a bright future for halo and keep buying on dips despite the fumbles by management. But we do call it out objectively and based on clear evidence when CEO makes a terrible mistake.

User Image Pittsburgh21 Posted - 2 days ago

$HALO Helen is obviously a rookie when it comes to these things and we are paying a dear price. Let’s make the change at the top and get strong leadership behind HALO and flourish.

User Image Sean29md Posted - 2 days ago

$HALO Evotec is playing games with Halozyme (the leak and now hiring MS to defend against the offer). Helen would gain respect and trust by showing discipline now and walking away.

User Image Sean29md Posted - 2 days ago

$HALO ... now that a rejection by Evotec is likely, if/when we get a hint that Helen won't chase them, Halozyme will rebound more meaningfully. https://seekingalpha.com/news/4306744-evotec-plunges-amid-report-its-against-halozyme-therapeutics-takeover

User Image NobVega Posted - 2 days ago

$HALO The market has spoken. Hope Helen gets the message.

User Image GSP Posted - 2 days ago

$HALO $SGMO $VERV $RGTI $SYM

User Image mickeyp_ Posted - 2 days ago

$HALO already over paying will they raise offer 😂😂😂😂

User Image OpenOutcrier Posted - 2 days ago

$EVO (-9.9% pre) Evotec plunges amid report it's against $HALO Halozyme Therapeutics takeover - SA https://ooc.bz/l/48671

User Image DesiMiami Posted - 2 days ago

$EVO The move down today most likely because of this 👇🏻: Deutsche Bank this morning basically says it's a bad idea for $HALO to buy $EVT $EVO at 11€/sh, as they maintain their PT to... 4€/s

User Image Sean29md Posted - 2 days ago

$HALO Helen on Bloomberg: https://youtu.be/HzjnD6VGGDg?si=QWste3X43hBxZelb She is not backing down on this acquisition SO FAR. Sad! We are paying the price for it.

User Image NobVega Posted - 2 days ago

$SMCI Sold some $HALO to buy this knocked out stock. 10 minutes later I'm happy. Sorry HALO. I'll be back when Helen backs off this buyout that's knocked the stock $18 in one week.

User Image GSP Posted - 2 days ago

The last 5 stocks in my video for November 19th: $HALO $VERV $SGMO $RGTI $SYM Watch here: https://greatstockpix.com/november-19th-day-trading-watch-list/ .

User Image Jamesiam Posted - 2 days ago

$HALO don’t forget it could go to $20 as it was $20.04 years ago

User Image kej32 Posted - 2 days ago

$HALO This is so sad. Don’t know what else to say!

User Image NobVega Posted - 2 days ago

$HALO The market has voted against this merger with their feet since the BOD hasn't stopped it. Sad.

User Image Windycity78 Posted - 2 days ago

$HALO Hard to believe this stock traded at a daily high of 62.13 on Nov. 11.

User Image Cutlass Posted - 2 days ago

$HALO Waiting for under 40 this month ⏰⏳📋

User Image maichol_snakes26 Posted - 3 days ago

$HALO is certainly down over the last few days mostly due to potential EVO news but do not forget that it is also down due to RFK appointment. Not discouraging folks from voicing their thoughts about acquisition, just want folks to keep RFK-health care dynamic that gets talked about for many other health care stocks (some of which are HALO collaborators) in consideration

User Image mickeyp_ Posted - 3 days ago

$HALO this has lost 2 billion in market cap since EVO buyout news... the value of the EVO buyout is 2 billion

User Image mickeyp_ Posted - 3 days ago

$HALO bought 5000 shares at 43

User Image NobVega Posted - 3 days ago

$HALO No dead cat bounce. No confidence in leadership. Will have to take the loss.

Analyst Ratings
JP Morgan Neutral Sep 19, 24
HC Wainwright & Co. Buy Sep 16, 24
HC Wainwright & Co. Buy Sep 13, 24
Benchmark Buy Aug 8, 24
HC Wainwright & Co. Buy Aug 8, 24
TD Cowen Buy Aug 7, 24
Morgan Stanley Overweight Aug 7, 24
JP Morgan Overweight Aug 6, 24
HC Wainwright & Co. Buy Aug 1, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Dec 12 Sell 40.14 20,000 802,800 151,911 12/13/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Dec 12 Option 12.65 20,000 253,000 161,911 12/13/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Oct 17 Sell 36.52 10,000 365,200 151,911 10/17/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Oct 17 Option 19.98 10,000 199,800 161,911 10/17/23
Torley Helen PRESIDENT AND CEO PRESIDENT AND CEO Aug 29 Sell 42.69 30,000 1,280,700 623,666 08/31/23
Torley Helen PRESIDENT AND CEO PRESIDENT AND CEO Aug 29 Option 13.87 30,000 416,100 633,666 08/31/23
Torley Helen PRESIDENT AND CEO PRESIDENT AND CEO Aug 15 Sell 43.49 30,000 1,304,700 623,666 08/17/23
Torley Helen PRESIDENT AND CEO PRESIDENT AND CEO Aug 15 Option 13.87 30,000 416,100 633,666 08/17/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Jun 21 Sell 36 10,000 360,000 141,911 06/22/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Jun 21 Option 18.41 10,000 184,100 151,911 06/22/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Apr 18 Option 18.41 10,000 184,100 151,911 04/19/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Apr 18 Sell 36 10,000 360,000 141,911 04/19/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Feb 27 Sell 49.55 10,000 495,500 138,927 02/28/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Feb 16 Sell 49.26 2,878 141,770 148,927 02/21/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Feb 16 Option 0 6,112 151,805 02/21/23
LaBrosse Nicole SVP, CHIEF FINANCIAL.. SVP, CHIEF FINANCIAL OFFICER Feb 16 Sell 49.26 2,525 124,382 9,066 02/21/23
LaBrosse Nicole SVP, CHIEF FINANCIAL.. SVP, CHIEF FINANCIAL OFFICER Feb 16 Option 0 5,094 11,591 02/21/23
Torley Helen PRESIDENT AND CEO PRESIDENT AND CEO Feb 16 Sell 49.26 11,061 544,865 633,666 02/21/23
Torley Helen PRESIDENT AND CEO PRESIDENT AND CEO Feb 16 Option 0 21,010 644,727 02/21/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Feb 15 Sell 48.39 10,000 483,900 143,477 02/17/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Feb 15 Option 0 3,386 146,863 02/17/23
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Jan 17 Sell 50.66 10,000 506,600 143,137 01/18/23
Torley Helen PRESIDENT AND CEO PRESIDENT AND CEO Dec 13 Option 14.66 30,000 439,800 597,177 12/15/22
Torley Helen PRESIDENT AND CEO PRESIDENT AND CEO Dec 13 Sell 58.31 30,000 1,749,300 587,177 12/15/22
LaBarre Michael J. SVP, CHIEF TECHNICAL.. SVP, CHIEF TECHNICAL OFFICER Dec 13 Sell 58.67 10,000 586,700 153,137 12/13/22
Posard Matthew L. Director Director Dec 02 Sell 56.89 30,000 1,706,700 105,189 12/06/22
Torley Helen President and CEO President and CEO Nov 08 Option 14.66 50,000 733,000 587,160 11/08/21
Torley Helen President and CEO President and CEO Nov 08 Sell 40.02 50,000 2,001,000 537,160 11/08/21
Torley Helen President and CEO President and CEO Sep 07 Sell 42.63 50,000 2,131,500 537,160 09/07/21
Torley Helen President and CEO President and CEO Sep 07 Option 14.66 50,000 733,000 587,160 09/07/21
Torley Helen President and CEO President and CEO Jun 07 Option 14.66 50,000 733,000 587,160 06/07/21
Torley Helen President and CEO President and CEO Jun 07 Sell 39.66 50,000 1,983,000 537,160 06/07/21
Torley Helen President and CEO President and CEO May 11 Option 14.66 50,000 733,000 587,160 05/11/21
Kelley Kenneth J Director Director Mar 01 Sell 45.67 5,000 228,350 184,833 03/01/21
Torley Helen President and CEO President and CEO Mar 01 Option 14.66 50,000 733,000 587,160 03/01/21
Torley Helen President and CEO President and CEO Mar 01 Sell 46.03 50,000 2,301,500 537,160 03/01/21
Kelley Kenneth J Director Director Feb 01 Sell 48.39 5,000 241,950 189,833 02/01/21
Torley Helen President and CEO President and CEO Feb 01 Option 14.66 50,000 733,000 520,522 02/01/21
Torley Helen President and CEO President and CEO Feb 01 Sell 48.13 50,000 2,406,500 470,522 02/01/21
LaBarre Michael J. SVP, Chief Technical.. SVP, Chief Technical Officer Dec 21 Sell 42.9 12,000 514,800 122,800 12/21/20
Kelley Kenneth J Director Director Nov 27 Sell 41.38 19,671 813,986 266,711 11/27/20
Torley Helen President and CEO President and CEO Nov 25 Option 14.66 50,000 733,000 530,522 11/25/20
Torley Helen President and CEO President and CEO Nov 25 Sell 40.68 50,000 2,034,000 480,522 11/25/20
LaBarre Michael J. SVP, Chief Technical.. SVP, Chief Technical Officer Nov 20 Sell 38.64 12,000 463,680 134,800 11/20/20